Tranylcypromine HCl is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively.
Tranylcypromine hemisulfate is a nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).
TRAP-6 (Thrombin Receptor Activator Peptide 6) is a peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist.
TRAP-6 (Thrombin Receptor Activator Peptide 6) is a peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist.
TRAP-6 (Thrombin Receptor Activator Peptide 6) is a peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist.
TRAP-6 (Thrombin Receptor Activator Peptide 6) is a peptide fragment (residues 42-47) of protease-activated receptor 1 (PAR1) that acts as a PAR1 agonist.
Terapidil is an antiplatelet compound that partially acts as a competitive inhibitor of phosphodiesterase inhibitors and platelet-derived growth factor (PDGF) receptors.
Terapidil is an antiplatelet compound that partially acts as a competitive inhibitor of phosphodiesterase inhibitors and platelet-derived growth factor (PDGF) receptors.
Terapidil is an antiplatelet compound that partially acts as a competitive inhibitor of phosphodiesterase inhibitors and platelet-derived growth factor (PDGF) receptors.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.